{
  "docId": "019de075-0f3e-7563-9ac8-6248b1eac169",
  "docSlug": "df5bd8b83b2912100a1eb82b66046bd0",
  "documentTitle": "Theravance Biopharma | Results Presentation Deck | 41 slides",
  "authorId": "theravance-biopharma",
  "authorName": "Theravance Biopharma",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 4,
  "pageCount": 41,
  "prevPage": 3,
  "nextPage": 5,
  "slideType": "key_messages",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-0f3e-7563-9ac8-6248b1eac169/4",
  "deckHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169",
  "deckJsonHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169.json",
  "deckAnchorHref": "/decks/019de075-0f3e-7563-9ac8-6248b1eac169#slide-4",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.96,
        "x": 0.02,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "1. Non-GAAP profit is expected to consist of GAAP income before taxes less share-based compensation expense and non-cash interest expense. 2. The first milestone payment, of $50.0 million, will be triggered if Royalty Pharma receives $240.0 million or more in royalty payments from GSK with respect to 2023 TRELEGY global net sales, which we would expect to occur in the event TRELEGY global net sales reach approximately $2.863 billion. MSA, multiple system atrophy; nOH, neurogenic orthostatic hypotension; PIFR, peak inspiratory flow rate.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4bdf39a-0190-4be8-a308-f2d31891adb0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.68,
        "y": 0.38
      },
      "kind": "list",
      "text": "Expanded Capital Return Program to $325M; Generate Non-GAAP Profit; $50M potential milestone",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4b2ef2ea-df20-440c-ab44-daafda965c5c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.06,
        "y": 0.38
      },
      "kind": "list",
      "text": "Continue YUPELRI Net Sales growth; Complete PIFR-2 study",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "94156003-b5fd-4dbf-8d58-bd95c65ea6f1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.3,
        "w": 0.28,
        "x": 0.37,
        "y": 0.38
      },
      "kind": "list",
      "text": "Initiate Phase 3 CYPRESS trial; Submit orphan drug designation",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e3d523cf-95b6-437a-9e15-0ad1f429df8f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.25,
        "x": 0.05,
        "y": 0.05
      },
      "kind": "title",
      "text": "2023 Targets",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "956ca2d5-de1f-4ab5-8d83-d609002fb391",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 4,
      "from": 1,
      "beatId": "2a623ddd-b1c1-4c41-94fc-d06bbfb941dc",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Attention",
      "beatSlug": "aida-attention",
      "evidence": "The presentation starts with an agenda and key messages, grabbing the audience's attention.",
      "position": 0,
      "confidence": 0.8,
      "parentBeatName": "Hook",
      "parentBeatSlug": "hook"
    },
    {
      "to": 4,
      "from": 4,
      "beatId": "5d053a84-4c89-4df9-af0b-fc1e37cf34f0",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Key Messages",
      "beatSlug": null,
      "evidence": "The presentation highlights key messages and 2023 targets.",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}